Darcey Black
Darcey Black has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Bob Humphries
TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany
2 shared publicationsSimon Cruwys
TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany
2 shared publications- Adam P. Croft
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
1 shared publication - Alexander Eckersley
The University of Manchester
1 shared publication - Alexander Nyström
Department of Dermatology, Medical Faculty, Medical Center - University of Freiburg, Freiburg, Germany
1 shared publication - Ali Mobasheri
Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
1 shared publication
Latest Publications
- Open Access
- 10 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1856
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.
- 10 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1856
Open AccessAdvances in Extracellular Matrix-Associated Diagnostics and Therapeutics
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM’s composition to restore its organization and function. Across diverse organ diseases, there are common denominators and distinguishing factors in this fibroinflammatory axis, which may be used to foster new insights into drug development across disease indications. The 2nd Extracellular Matrix Pharmacology Congress took place in Copenhagen, Denmark, from 17 to 19 June 2024 and was hosted by the International Society of Extracellular Matrix Pharmacology. The event was attended by 450 participants from 35 countries, among whom were prominent scientists who brought together state-of-the-art research on organ diseases and asked important questions to facilitate drug development. We highlight key aspects of the ECM in the liver, kidney, skin, intestine, musculoskeletal system, lungs, and solid tumors to advance our understanding of the ECM and its central targets in drug development. We also highlight key advances in the tools and technology that enable this drug development, thereby supporting the ECM.
- 11 October 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (11) , 104207
Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
- 11 October 2024
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (11) , 104207
Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
- 1 December 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (12) , 2277-2283
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
- 1 December 2020
- Published by Elsevier in Drug Discovery Today
- Vol. 25 (12) , 2277-2283
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities
- 1 November 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21) , 6027-6031
Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model
- 1 November 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21) , 6027-6031
Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model